Patient-Identified Problems and Influences Associated With Diagnostic Delay of Acromegaly: A Nationwide Cross-Sectional Study

Background Insidious-onset acromegaly may easily be overlooked by non-specialists of acromegaly and cause diagnostic delay. This study aims to examine the association between diagnostic delay and advice from doctors before any confirmed diagnosis and subsequent comorbidities, and elicit patient-perceived reasons for misdiagnoses. Methods An online nationwide cross-sectional study was conducted through China Acromegaly Patient Association. Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) levels at diagnosis and cancerous, endocrine-metabolic, musculoskeletal, cardiovascular, respiratory, and psychiatric comorbidities were reported by patients. The association between diagnostic delay and pre-diagnostic advice from doctors as well as subsequent comorbidities after diagnosis were examined. Results In total, 447 valid responses were collected. Overall, 58.8% patients experienced misdiagnoses, and 22.6% had diagnostic delay. Before arriving at any diagnosis, patients without treatment (adjusted odds ratio [AOR]: 3.66, 95% confidence interval [CI]: 1.30-10.33) or receiving treatment to symptoms only (AOR: 7.05, 95%CI: 4.09-12.17) had greater chance of being misdiagnosed, and hence had diagnostic delay. Patients believed insufficient specialists, limited awareness of acromegaly of non-specialists and poor doctor-patient communications were major reasons of misdiagnosis. Diagnostic delay were associated with higher GH level at diagnosis and endocrine-metabolic, musculoskeletal and cardiovascular comorbidities (all P<0.05). Conclusions Suboptimal pre-diagnostic advice for patients, reflecting limited awareness of acromegaly among non-specialists, may delay the diagnosis and increase comorbidities. Feedbacks on the patients’ final diagnosis from specialists to non-specialists should be considered, and doctor-patient communication and clinical decision-making process should be improved. Comorbidities should be screened and monitored particularly for patients with diagnostic delay.

[1]  Shuyang Zhang,et al.  Quality of life and its determinants in patients with treated acromegaly: a cross-sectional nationwide study in China. , 2020, The Journal of clinical endocrinology and metabolism.

[2]  G. Johannsson,et al.  Prolonged Diagnostic Delay in Acromegaly is Associated with Increased Morbidity and Mortality. , 2020, European journal of endocrinology.

[3]  S. Webb,et al.  Patient-Centered Outcomes with Pituitary and Parasellar Disease , 2020, Neuroendocrinology.

[4]  F. Casanueva,et al.  A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. , 2020, The Journal of clinical endocrinology and metabolism.

[5]  L. Kasuki,et al.  Determinants of morbidities and mortality in acromegaly , 2019, Archives of endocrinology and metabolism.

[6]  F. Stiefel,et al.  General practitioners referring patients to specialists in tertiary healthcare: a qualitative study , 2019, BMC Family Practice.

[7]  L. Verneuil,et al.  Patients' perspectives on acromegaly diagnostic delay: a qualitative study. , 2019, European journal of endocrinology.

[8]  M. Marazuela,et al.  Bringing Cardiovascular Comorbidities in Acromegaly to an Update. How Should We Diagnose and Manage Them? , 2019, Front. Endocrinol..

[9]  C. Boguszewski,et al.  Growth Hormone's Links to Cancer. , 2018, Endocrine reviews.

[10]  P. Chanson,et al.  Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study , 2018, Endocrine.

[11]  M. Fleseriu,et al.  Updates in Diagnosis and Treatment of Acromegaly , 2018, European endocrinology.

[12]  Salma M. AlDallal.  Acromegaly: a challenging condition to diagnose , 2018, International journal of general medicine.

[13]  P. Chanson,et al.  Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile? , 2018, Endocrine.

[14]  Xiangyi Kong,et al.  Automatic Detection of Acromegaly From Facial Photographs Using Machine Learning Methods , 2017, EBioMedicine.

[15]  Xinqi Cheng,et al.  Reference ranges for serum insulin-like growth factor I (IGF-I) in healthy Chinese adults , 2017, PloS one.

[16]  P. Chanson,et al.  Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. , 2017, European journal of endocrinology.

[17]  S. Melmed.  Chapter 15 – Acromegaly , 2017 .

[18]  L. Vilar,et al.  Acromegaly: clinical features at diagnosis , 2017, Pituitary.

[19]  N. Karavitaki,et al.  Epidemiology of acromegaly: review of population studies , 2016, Pituitary.

[20]  T. Brue,et al.  The risks of overlooking the diagnosis of secreting pituitary adenomas , 2016, Orphanet Journal of Rare Diseases.

[21]  Paul Hamilton,et al.  The thinking doctor: clinical decision making in contemporary medicine. , 2016, Clinical medicine.

[22]  J. Abucham,et al.  Challenges in the diagnosis and management of acromegaly: a focus on comorbidities , 2016, Pituitary.

[23]  M. Peppa,et al.  High incidence of thyroid cancer among patients with acromegaly. , 2016, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[24]  O. Bruno,et al.  Implementing a screening program for acromegaly in Latin America: necessity versus feasibility , 2016, Pituitary.

[25]  C. Dimopoulou,et al.  Health Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life , 2015, Front. Endocrinol..

[26]  C. Rhodes,et al.  Patient perspectives on the impact of acromegaly: results from individual and group interviews , 2014, Patient preference and adherence.

[27]  I. Kreitschmann-Andermahr,et al.  Diagnostic delay is associated with psychosocial impairment in acromegaly , 2013, Pituitary.

[28]  P. Chanson,et al.  A consensus on the diagnosis and treatment of acromegaly complications , 2012, Pituitary.

[29]  S. Cannavò,et al.  Predictors of morbidity and mortality in acromegaly: an Italian survey. , 2012, European journal of endocrinology.

[30]  Carsten Schultz,et al.  How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient-physician interaction. , 2012, Health policy.

[31]  F. Cordido,et al.  Clinical Manifestations and Diagnosis of Acromegaly , 2012, International journal of endocrinology.

[32]  Rolf P. Würtz,et al.  A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification. , 2011, The Journal of clinical endocrinology and metabolism.

[33]  O. Celik,et al.  Thyroid cancer is the most common cancer associated with acromegaly , 2010, Pituitary.

[34]  W. Ludlam.  Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK) , 2010 .

[35]  Hang Lee,et al.  Changing patterns in diagnosis and therapy of acromegaly over two decades. , 2008, The Journal of clinical endocrinology and metabolism.

[36]  R. Kravitz,et al.  Reasons for outpatient referrals from generalists to specialists , 1999, Journal of General Internal Medicine.

[37]  G. Gamble,et al.  Factors influencing mortality in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.